시장보고서
상품코드
1148283

CAR-T 치료 시장(2022-2032년)

CAR-T Therapy Market Report 2022-2032

발행일: | 리서치사: Visiongain Reports Ltd. | 페이지 정보: 영문 251 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 CAR-T 치료 시장 규모는 2021년에 19억 달러에 달했습니다. 시장은 예측기간인 2022-2032년간 42.95%의 CAGR로 확대될 것으로 예측됩니다.

세계의 CAR-T 치료(CAR-T Therapy) 시장에 대해 조사했으며, 시장 개요와 함께 적응증별, 종류별, 표적 항원별, 환자별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업 개요 등을 제공하고 있습니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

  • 주요 조사 결과
  • 시장 역학
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
    • 시장 기회
  • COVID-19의 영향 분석
  • Porter's Five Forces 분석
  • PEST 분석

제4장 CAR-T 치료 시장 분석, 적응증별

  • 주요 조사 결과
  • 적응 부문 : 시장 매력 지수
  • CAR-T 치료 시장 규모 예측, 적응증별
  • 미만성거대B세포림프종(DLBCL)
  • 급성 림프아구성 백혈병(ALL)
  • 소포림프종
  • 다발성 골수종(MM)
  • 기타

제5장 CAR-T 치료 시장 분석, 종류별

  • 주요 조사 결과
  • 종류 부문 : 시장 매력 지수
  • CAR-T 치료 시장 규모 예측, 종류별
  • Abecma
  • Yescarta
  • Kymriah
  • Tecartus
  • 기타

제6장 CAR-T 치료 시장 분석, 표적 항원별

  • 주요 조사 결과
  • 표적 항원 부문 : 시장 매력 지수
  • CAR-T 치료 시장 규모 예측, 표적 항원별
  • CD19/CD22
  • BCMA(B세포 성숙 항원)
  • 기타

제7장 CAR-T 치료 시장 분석, 환자별

  • 주요 조사 결과
  • 환자 부문 : 시장 매력 지수
  • CAR-T 치료 시장 규모 예측, 환자별
  • 아동
  • 성인
  • 고령자

제8장 CAR-T 치료 시장 분석, 최종사용자별

  • 주요 조사 결과
  • 최종사용자 부문 : 시장 매력 지수
  • CAR-T 치료 시장 규모 예측, 최종사용자별
  • 병원
  • 전문 클리닉
  • 기타

제9장 CAR-T 치료 시장 분석, 지역별

  • 주요 조사 결과
  • 시장 규모 예측, 지역별

제10장 북미의 CAR-T 치료 시장 분석

제11장 유럽의 CAR-T 치료 시장 분석

제12장 아시아태평양의 CAR-T 치료 시장 분석

제13장 라틴아메리카의 CAR-T 치료 시장 분석

제14장 중동 및 아프리카의 CAR-T 치료 시장 분석

제15장 기업 개요

  • 경쟁 상황, 2021년
  • 전략적 전망
  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Private Limited
  • bluebird bio, Inc.
  • GSK plc
  • Caribou Biosciences Inc
  • Amgen Inc.
  • AbbVie Inc.
  • BioNTech SE

제16장 결론과 제안

KSM 22.11.24

The CAR-T Therapy market was valued at US$1.9 billion in 2021 and is projected to grow at a CAGR of 42.95% during the forecast period 2022-2032.

The CAR-T Therapy Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Factors Such As Increase in Funding From Venture Capitalist And Government Institutes And Increase In Global Burden of Cancer Benefits Are Driving the Market Growth

Some of the major forces propelling the CAR-T Therapy market include increase in funding from venture capitalist and government institutes and increase in global burden of cancer benefits. As per the data published by the WHO, cancer is a leading cause of death globally and caused almost 10 million deaths in 2020.

Based on current and projected population aging and growth, the American Cancer Society, Inc., predicts that the burden of cancer will increase to an estimated 29.4 million cases globally by 2040. China, with the largest population size worldwide has the highest global proportion of cancer new cases and deaths followed by Northern America in terms of new cases and fourth by cancer deaths. Increase in consumption of tobacco & alcohol, unhealthy diet, physical inactivity, and air pollution in various countries across the globe might further increase the cancer burden in future. In the past five years around US$12 billion have been invested by venture capital (VC) firms around the globe, an additional of US$2.2 billion of funding is raised through strategic partnerships between various institutes and biopharma companies.

Reimbursement Challenges and Side-effects of CAR-T Therapy

Reimbursement of CAR-T cell therapies has been a challenge to the healthcare providers, insurers and national & regional government agencies worldwide. CAR-T cell is amongst the most expensive drugs on the market with a price tag of around US$450,000 to US$500,000 per patient. Moreover, patient opting for CAR-T cell often have aggressive deceases resulting in rapid deterioration of health and thus any delays in payer approval can affect patient eligibility for CAR-T cell. Like every other cancer treatment, CAR-T cell therapy also poses severe side effects. Some of the most common occurring side effects are the cytokine release syndrome (CRS) and neurological effects.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the CAR-T Therapy market evolving?
  • What is driving and restraining the CAR-T Therapy market?
  • How will each CAR-T Therapy submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
  • How will the market shares for each CAR-T Therapy submarket develop from 2022 to 2032?
  • What will be the main driver for the overall market from 2022 to 2032?
  • Will leading CAR-T Therapy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the CAR-T Therapy projects for these leading companies?
  • How will the industry evolve during the period between 2022 and 2032? What are the implications of CAR-T Therapy projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the CAR-T Therapy market?
  • Where is the CAR-T Therapy market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the CAR-T Therapy market today, and over the next 10 years:

  • Our 251-page report provides 99 tables and 149 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the CAR-T Therapy market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising CAR-T Therapy prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

Indication

  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Acute Lymphoblastic Leukemia (ALL)
  • Follicular Lymphoma
  • Multiple Myeloma (MM)
  • Others

Type

  • Abecma
  • Yescarta
  • Kymriah
  • Tecartus
  • Other

Target Antigens

  • CD19/CD22
  • BCMA (B-cell maturation antigen)
  • Others

Patient

  • Children
  • Adults
  • Seniors

End User

  • Hospitals
  • Specialty Clinics
  • Other End User

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 10 leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

MEA

The report also includes profiles and for some of the leading companies in the CAR-T Therapy Market, 2022 to 2032, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth

  • AbbVie Inc.
  • Amgen Inc.
  • BioNTech SE
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Caribou Biosciences Inc.
  • Gilead Sciences Inc.
  • GSK plc
  • Johnson & Johnson Private Limited
  • Novartis AG

Overall world revenue for CAR-T Therapy Market, 2022 to 2032 in terms of value the market will surpass US$2.8 billion in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the CAR-T Therapy Market, 2022 to 2032 report help you?

In summary, our 250+ page report provides you with the following knowledge:

  • Revenue forecasts to 2032 for CAR-T Therapy Market, 2022 to 2032 Market, with forecasts for indication, type, target antigens, patient, and end-users, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2032 for five regional and 12 key national markets - See forecasts for the CAR-T Therapy Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Germany, France, UK, Italy, Netherlands, China, India, Japan, South Korea, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 10 of the major companies involved in the CAR-T Therapy Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the CAR-T Therapy Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to CAR-T Therapy Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Reports
  • 1.10 About

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Increasing Global Burden of Cancer Boosting Demand for CAR T Cell
      • 3.2.1.2 Increase in Funding from Venture Capitalist and Government Institutes
      • 3.2.1.3 Expanding Clinical Research Infrastructure in China
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Complex Manufacturing and Supply Chain
      • 3.2.2.2 Reimbursement Challenges for CAR-T cell
      • 3.2.2.3 Side Effects of CAR-T cell Therapy
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Growing Use of AI in CAR-T Cell Manufacturing
      • 3.2.3.2 Engineering Controllable CAR-T Cells
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Threat of New Entrants
    • 3.4.4 Threat of Substitutes
    • 3.4.5 Competitive Rivalry
  • 3.5 PEST Analysis
    • 3.5.1 Political
    • 3.5.2 Economic
    • 3.5.3 Social
    • 3.5.4 Technological

4 Car-T Therapy Market Analysis By Indication

  • 4.1 Key Findings
  • 4.2 Indication Segment: Market Attractiveness Index
  • 4.3 Car-T Therapy Market Size Estimation and Forecast by Indication
  • 4.4 Diffuse Large B-Cell Lymphoma (DLBCL)
    • 4.4.1 Market Size by Region, 2022-2032 (US$ bn)
    • 4.4.2 Market Share by Region, 2022 & 2032 (%)
  • 4.5 Acute Lymphoblastic Leukaemia (ALL)
    • 4.5.1 Market Size by Region, 2022-2032 (US$ bn)
    • 4.5.2 Market Share by Region, 2022 & 2032 (%)
  • 4.6 Follicular Lymphoma
    • 4.6.1 Market Size by Region, 2022-2032 (US$ bn)
    • 4.6.2 Market Share by Region, 2022 & 2032 (%)
  • 4.7 Multiple Myeloma (MM)
    • 4.7.1 Market Size by Region, 2022-2032 (US$ bn)
    • 4.7.2 Market Share by Region, 2022 & 2032 (%)
  • 4.8 Others
    • 4.8.1 Market Size by Region, 2022-2032 (US$ bn)
    • 4.8.2 Market Share by Region, 2022 & 2032 (%)

5 Car-T Therapy Market Analysis By Type

  • 5.1 Key Findings
  • 5.2 Type Segment: Market Attractiveness Index
  • 5.3 Car-T Therapy Market Size Estimation and Forecast By Type
  • 5.4 Abecma
    • 5.4.1 Abecma Market Size, 2022-2032 (US$ bn)
  • 5.5 Yescarta
    • 5.5.1 Yescarta Market Size, 2022-2032 (US$ bn)
  • 5.6 Kymriah
    • 5.6.1 Kymriah Market Size, 2022-2032 (US$ bn)
  • 5.7 Tecartus
    • 5.7.1 Tecartus Market Size, 2022-2032 (US$ bn)
  • 5.8 Others
    • 5.8.1 Others Market Size, 2022-2032 (US$ bn)

6 Car-T Therapy Market Analysis By Target Antigens

  • 6.1 Key Findings
  • 6.2 Target Antigens Segment: Market Attractiveness Index
  • 6.3 Car-T Therapy Market Size Estimation and Forecast By Target Antigens
  • 6.4 CD19/CD22
    • 6.4.1 Market Size by Region, 2022-2032 (US$ bn)
    • 6.4.2 Market Share by Region, 2022 & 2032 (%)
  • 6.5 BCMA (B-cell maturation antigen)
    • 6.5.1 Market Size by Region, 2022-2032 (US$ bn)
    • 6.5.2 Market Share by Region, 2022 & 2032 (%)
  • 6.6 Others
    • 6.6.1 Market Size by Region, 2022-2032 (US$ bn)
    • 6.6.2 Market Share by Region, 2022 & 2032 (%)

7 Car-T Therapy Market Analysis By Patient

  • 7.1 Key Findings
  • 7.2 Patient Segment: Market Attractiveness Index
  • 7.3 Car-T Therapy Market Size Estimation and Forecast By Patient
  • 7.4 Children
    • 7.4.1 Market Size by Region, 2022-2032 (US$ bn)
    • 7.4.2 Market Share by Region, 2022 & 2032 (%)
  • 7.5 Adults
    • 7.5.1 Market Size by Region, 2022-2032 (US$ bn)
    • 7.5.2 Market Share by Region, 2022 & 2032 (%)
  • 7.6 Seniors
    • 7.6.1 Market Size by Region, 2022-2032 (US$ bn)
    • 7.6.2 Market Share by Region, 2022 & 2032 (%)

8 Car-T Therapy Market Analysis By End-users

  • 8.1 Key Findings
  • 8.2 End User Segment: Market Attractiveness Index
  • 8.3 Car-T Therapy Market Size Estimation and Forecast By End-users
  • 8.4 Hospitals
    • 8.4.1 Market Size by Region, 2022-2032 (US$ bn)
    • 8.4.2 Market Share by Region, 2022 & 2032 (%)
  • 8.5 Specialty Clinics
    • 8.5.1 Market Size by Region, 2022-2032 (US$ bn)
    • 8.5.2 Market Share by Region, 2022 & 2032 (%)
  • 8.6 Other End-user
    • 8.6.1 Market Size by Region, 2022-2032 (US$ bn)
    • 8.6.2 Market Share by Region, 2022 & 2032 (%)

9 Car-T Therapy Market Analysis by Region

  • 9.1 Key Findings
  • 9.2 Regional Market Size Estimation and Forecast

10 North America Car-T Therapy Market Analysis

  • 10.1 Key Findings
  • 10.2 North America Car-T Therapy Market Attractiveness Index
  • 10.3 North America Car-T Therapy Market by Country, 2022, 2027 & 2032 (US$ bn)
  • 10.4 North America Car-T Therapy Market Size Estimation and Forecast by Country
  • 10.5 North America Car-T Therapy Market Size Estimation and Forecast by Indication
  • 10.6 North America Car-T Therapy Market Size Estimation and Forecast by Target Antigens
  • 10.7 North America Car-T Therapy Market Size Estimation and Forecast by Patients
  • 10.8 North America Car-T Therapy Market Size Estimation and Forecast by End Users
  • 10.9 U.S. Car-T Therapy Market Analysis
  • 10.10 Canada Car-T Therapy Market Analysis

11 Europe Car-T Therapy Market Analysis

  • 11.1 Key Findings
  • 11.2 Europe Car-T Therapy Market Attractiveness Index
  • 11.3 Europe Car-T Therapy Market by Country, 2022, 2027 & 2032 (US$ bn)
  • 11.4 Europe Car-T Therapy Market Size Estimation and Forecast by Country
  • 11.5 Europe Car-T Therapy Market Size Estimation and Forecast By Indication
  • 11.6 Europe Car-T Therapy Market Size Estimation and Forecast by Target Antigens
  • 11.7 Europe Car-T Therapy Market Size Estimation and Forecast by Patients
  • 11.8 Europe Car-T Therapy Market Size Estimation and Forecast by End-users
  • 11.9 Germany Car-T Therapy Market Analysis
  • 11.10 UK Car-T Therapy Market Analysis
  • 11.11 France Car-T Therapy Market Analysis
  • 11.12 Italy Car-T Therapy Market Analysis
  • 11.13 Spain Car-T Therapy Market Analysis
  • 11.14 Netherlands Car-T Therapy Market Analysis
  • 11.15 Rest of Europe Car-T Therapy Market Analysis

12 Asia Pacific Car-T Therapy Market Analysis

  • 12.1 Key Findings
  • 12.2 Asia Pacific Car-T Therapy Market Attractiveness Index
  • 12.3 Asia Pacific Car-T Therapy Market by Country, 2022, 2027 & 2032 (US$ bn)
  • 12.4 Asia Pacific Car-T Therapy Market Size Estimation and Forecast by Country
  • 12.5 Asia Pacific Car-T Therapy Market Size Estimation and Forecast By Indication
  • 12.6 Asia Pacific Car-T Therapy Market Size Estimation and Forecast by Target Antigens
  • 12.7 Asia Pacific Car-T Therapy Market Size Estimation and Forecast by Patients
  • 12.8 Asia Pacific Car-T Therapy Market Size Estimation and Forecast by End-users
  • 12.9 Japan Car-T Therapy Market Analysis
  • 12.10 China Car-T Therapy Market Analysis
  • 12.11 India Car-T Therapy Market Analysis
  • 12.12 Australia Car-T Therapy Market Analysis
  • 12.13 South Korea Car-T Therapy Market Analysis
  • 12.14 Rest of Asia Pacific Car-T Therapy Market Analysis

13 Latin America Car-T Therapy Market Analysis

  • 13.1 Key Findings
  • 13.2 Latin America Car-T Therapy Market Size Estimation and Forecast By Indication
  • 13.3 Latin America Car-T Therapy Market Size Estimation and Forecast by Target Antigens
  • 13.4 Latin America Car-T Therapy Market Size Estimation and Forecast by Patients
  • 13.5 Latin America Car-T Therapy Market Size Estimation and Forecast by End-users
  • 13.6 Brazil Car-T Therapy Market Analysis
  • 13.7 Mexico Car-T Therapy Market Analysis
  • 13.8 Rest of Latin America Car-T Therapy Market Analysis

14 MEA Car-T Therapy Market Analysis

  • 14.1 Key Findings
  • 14.2 MEA Car-T Therapy Market Size Estimation and Forecast By Indication
  • 14.3 MEA Car-T Therapy Market Size Estimation and Forecast by Target Antigens
  • 14.4 MEA Car-T Therapy Market Size Estimation and Forecast by Patient
  • 14.5 MEA Car-T Therapy Market Size Estimation and Forecast by End-users
  • 14.6 GCC Car-T Therapy Market Analysis
  • 14.7 Rest of Middle East and Africa Car-T Therapy Market Analysis

15 Company Profiles

  • 15.1 Competitive Landscape, 2021
  • 15.2 Strategic Outlook
  • 15.3 Novartis AG
    • 15.3.1 Company Snapshot
    • 15.3.2 Company Overview
    • 15.3.3 Financial Analysis
      • 15.3.3.1 Net Revenue, 2017-2021
      • 15.3.3.2 R&D, 2017-2021
      • 15.3.3.3 Regional Market Shares, 2021
    • 15.3.4 Product Benchmarking
    • 15.3.5 Strategic Outlook
  • 15.4 Gilead Sciences, Inc.
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Financial Analysis
      • 15.4.3.1 Net Revenue, 2017-2021
      • 15.4.3.2 R&D, 2017-2021
      • 15.4.3.3 Regional Market Shares, 2021
    • 15.4.4 Product Benchmarking
    • 15.4.5 Strategic Outlook
  • 15.5 Bristol-Myers Squibb Company
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Financial Analysis
      • 15.5.3.1 Net Revenue, 2017-2021
      • 15.5.3.2 R&D, 2017-2021
      • 15.5.3.3 Regional Market Shares, 2021
    • 15.5.4 Product Benchmarking
    • 15.5.5 Strategic Outlook
  • 15.6 Johnson & Johnson Private Limited
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Financial Analysis
      • 15.6.3.1 Net Revenue, 2017-2021
      • 15.6.3.2 R&D, 2017-2021
      • 15.6.3.3 Regional Market Shares, 2021
    • 15.6.4 Product Benchmarking
    • 15.6.5 Strategic Outlook
  • 15.7 bluebird bio, Inc.
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Financial Analysis
      • 15.7.3.1 Net Revenue, 2017-2021
      • 15.7.3.2 R&D, 2017-2021
    • 15.7.4 Product Benchmarking
    • 15.7.5 Strategic Outlook
  • 15.8 GSK plc
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Financial Analysis
      • 15.8.3.1 Net Revenue, 2017-2021
      • 15.8.3.2 R&D, 2017-2021
      • 15.8.3.3 Regional Market Shares, 2021
    • 15.8.4 Product Benchmarking
    • 15.8.5 Strategic Outlook
  • 15.9 Caribou Biosciences Inc
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Financial Analysis
      • 15.9.3.1 Net Revenue, 2019-2021
      • 15.9.3.2 R&D, 2019-2021
      • 15.9.3.3 Regional Market Shares, 2021
    • 15.9.4 Product Benchmarking
    • 15.9.5 Strategic Outlook
  • 15.10 Amgen Inc.
    • 15.10.1 Company Snapshot
    • 15.10.2 Company Overview
    • 15.10.3 Financial Analysis
      • 15.10.3.1 Net Revenue, 2017-2021
      • 15.10.3.2 R&D, 2017-2021
      • 15.10.3.3 Regional Market Shares, 2021
    • 15.10.4 Product Benchmarking
    • 15.10.5 Strategic Outlook
  • 15.11 AbbVie Inc.
    • 15.11.1 Company Snapshot
    • 15.11.2 Company Overview
    • 15.11.3 Financial Analysis
      • 15.11.3.1 Net Revenue, 2017-2021
      • 15.11.3.2 R&D, 2017-2021
      • 15.11.3.3 Regional Market Shares, 2021
    • 15.11.4 Product Benchmarking
    • 15.11.5 Strategic Outlook
  • 15.12 BioNTech SE
    • 15.12.1 Company Snapshot
    • 15.12.2 Company Overview
    • 15.12.3 Financial Analysis
      • 15.12.3.1 Net Revenue, 2017-2021
      • 15.12.3.2 R&D, 2017-2021
    • 15.12.4 Product Benchmarking
    • 15.12.5 Strategic Outlook

16 Conclusion and Recommendations

  • 16.1 Concluding Remarks from
  • 16.2 Recommendations for Market Players
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제